PETALING JAYA: Private healthcare players are cautiously supportive of Malaysia’s proposed Medical and Health Insurance/Takaful (MHIT) framework, but warn that affordability reforms must not come at the expense of treatment quality, specialist access or patient flexibility.
The Malaysian Medical Association (MMA) said that while it supports the intent behind MHIT, any cost-sharing structures involving deductibles or co-payments must be carefully designed to avoid discouraging patients from seeking treatment.
MMA president Datuk Dr Thirunavukarasu Rajoo said there is a real risk that patients may delay treatment or skip follow-ups due to concerns over out-of-pocket costs.
“Delayed care often means more serious illness later.”
He added that older Malaysians would likely be hit hardest as they tend to require more frequent consultations, chronic disease management and specialist care despite being on lower or fixed incomes.
“Any co-payment or deductible system must include safeguards. Premium structures and policy terms must remain transparent and predictable so that patients can make informed decisions.”
Reforms should focus on addressing the root causes of medical inflation instead of merely shifting costs to patients, he noted.
“Malaysia needs a balanced approach that protects both affordability and access to care.
“Any insurance reform must include consumer protection so that patients are not deterred from seeking timely, appropriate treatment because of cost.”
Association of Private Hospitals Malaysia (APHM) president Datuk Dr Kuljit Singh said one of the key concerns surrounding MHIT’s proposed tier and package-based financing model is the wide variation in patient conditions and treatment complexity.
“A relatively healthy young patient may require very different care compared to an older patient with multiple chronic illnesses, even for the same condition.”
Dr Kuljit said these differences naturally affect treatment complexity, resource usage and costs.
He said APHM is calling for a value-based healthcare model, where pricing frameworks remain flexible enough to account for clinical differences without compromising quality of care or future investments.
It is still too early to determine how MHIT would affect private healthcare utilisation patterns, hospital participation or affordability outcomes, he added.
“We will need to observe its implementation first to properly evaluate its effectiveness.”
